NewAmsterdam Pharma
Developing transformative, clinically validated oral therapies for patients with metabolic diseases.
Launch date
Employees
Market cap
CAD2.0b
Enterprise valuation
CAD1.4b (Public information from Sep 2024)
Share price
$16.06 NAMS
Naarden North Holland (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | - | - | 97.5m | 12.8m | 9.9m | 5.8m |
| % growth | - | - | - | (87 %) | (22 %) | (42 %) |
| EBITDA | (5.4m) | (29.8m) | (6.9m) | (156m) | - | - |
| % EBITDA margin | - | - | (7 %) | (1218 %) | - | - |
| Profit | (5.7m) | (28.6m) | (78.1m) | (161m) | - | - |
| % profit margin | - | - | (80 %) | (1256 %) | - | - |
| R&D budget | 4.0m | 25.2m | 82.5m | 145m | - | - |
| R&D % of revenue | - | - | 85 % | 1131 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | - | |
* | €160m | Series A | |
* | $120m Valuation: $326m -9.9x EV/LTM EBITDA | SPAC IPO | |
* | $235m Valuation: $326m -9.9x EV/LTM EBITDA | SPAC Private Placement | |
* | N/A | N/A | Secondary |
* | N/A | $175m | Post IPO Equity |
| Total Funding | CAD560m | ||
Related Content
Recent News about NewAmsterdam Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.